Bulls Pile Into Nektar Therapeutics

By David Russell, reporter at OptionMonster

NEW YORK -- Nektar Therapeutics ( NKTR) has been trending higher, and traders cleaned up in the name Thursday.

OptionMonster's tracking systems detected a spike of buying in the September 12 calls late in the morning, mostly for $1.25 and $1.35. These long calls locked in the price where shares can be purchased in the drug developer, giving them potentially explosive leverage in a rally.

That's exactly what happened Thursday. Nektar's stock was up some 5% when the option trades hit, then climbed 13% to close the session at $12.69. The calls, by contrast, shot up more than 75% to $2.40.

The stock has been swinging widely since late 2011 while making steadily higher lows. Thursday's bounce occurred around the same $11.10 level where it peaked in March and April, which could make some chart watchers think that it's in a bullish uptrend.

Volume approached 9,500 at the strike. Previous open interest was just 473 contracts, indicating that new capital was put to work.

Overall calls in the name outnumbered puts by an extremely bullish 52-to-1 ratio. Total option volume was 12 times greater than average.

Russell has no positions in NKTR.
This commentary comes from an independent investor or market observer as part of TheStreet guest contributor program. The views expressed are those of the author and do not necessarily represent the views of TheStreet or its management.

If you liked this article you might like

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Nektar Shares Boosted by Promising Results on Opioid Addiction Study

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct